PURPOSE: To describe a case of exudative macular detachment secondary to peripheral exudative chorioretinopathy with a favorable anatomic and visual outcome following treatment with intravitreal bevacizumab. METHODS: The medical records of a patient with peripheral exudative chorioretinopathy were reviewed. RESULTS: Macular reattachment was achieved with a corresponding visual acuity improvement that was maintained over an uncomplicated 17-month clinical course. CONCLUSIONS: Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.
No takes yet. Share an insight, caveat, or question.
Barkmeier et al. (2011) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: